GRCE

AI MemoPost-earnings T+3

Grace Therapeutics

As of 2026-08-08/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FY2026 results show lower reported loss but remain pre-commercial • 2026-06-18

Base target: $2 / p=45% prob

Biggest risk

The April CRL remains unresolved on CMC, non-clinical, cGMP, and manufacturing matters, and the company has not disclosed a dated resubmission. No analyst revisions, target changes, or post-print estimate changes are available.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Regulatory clarity improved because the Type A materials reportedly found no clinical deficiencies or need for additional clinical data; fresh financing also supports remediation and resubmission efforts. [#SEC-8K-2026-07-28] [#SEC-8K-2026-08-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-08

Base target

p=45%

Bull target

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Private placement extends runway but adds dilution pressure
Potential GTx-104 NDA resubmission and approval
Regulatory clarity improved because the Type A materials reportedly found no clinical deficiencies or need for additional clinical data; fresh financing also supports remediation and resubmission efforts.

BearKey bullets

FDA remediation may take longer than expected or fail to support NDA resubmission.
Low coverage and loose peers materially limit valuation confidence.
Manufacturing, leachables, toxicology, and cGMP issues remain execution risks despite no identified clinical deficiencies.

WatchKey bullets

FY2026 results show lower reported loss but remain pre-commercial

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $2 (p=45%)

Target spread vs base: +150% / -50%

Scenario probabilities

Bull Target: $5 (p=20%)Base Target: $2 (p=45%)Bear Target: $1 (p=35%)

Commentary

The scheduled August 6 post-earnings packet did not provide a new earnings release, consensus comparison, analyst reaction, or target revisions. The retrieved August 6 SEC filing was a financing update rather than operating results; the latest available quote near $2.13 is only modestly above the $2.12 anchor. Primary evidence is constructive on regulatory clarity but forward visibility remains weak, so this is a monitoring-style view.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Private placement extends runway but adds dilution pressure
Potential GTx-104 NDA resubmission and approval

Scenarios

Bull Target (Scenario probability)

$5 / p=20% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=35% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-18
FY2026 results show lower reported loss but remain pre-commercial
Grace reported a FY2026 net loss of $7.8 million versus $9.6 million previously; R&D expense fell to $2.4 million largely after completion of the pivotal safety trial, while NDA-support costs continued. [#SEC-8K-2026-06-18] [#PR-EARNINGS-2026-06-18]
Prob 100.00% • Move 0.00% • Priced-in 90.00%
EVENT2026-11-06
Regulatory remediation and NDA resubmission path
Type A meeting minutes reportedly indicated no clinical safety or efficacy deficiency and no request for additional clinical data, but CMC, non-clinical, cGMP, and manufacturing remediation remain. No resubmission date is disclosed. [#SEC-8K-2026-07-28]
Prob 60.00% • Move 15.00% • Priced-in 65.00%

Short-term Catalysts

Next few weeks

Private placement extends runway but adds dilution pressure
2026-08-06
The August offering sold 4,761,904 shares at $2.10 and generated approximately $10 million gross proceeds before expenses. The capital is supportive, but the enlarged share count may cap near-term upside. [#SEC-8K-2026-08-06] [#8-K-2026-08-06]
Prob 100% • Move -5% • Priced-in 85%

Long-term Catalysts

Months to a year

Potential GTx-104 NDA resubmission and approval
2027-08-08
Approval remains the principal upside path for the company’s lead asset, but timing and outcome depend on remediation and FDA review after the April CRL. [#SEC-10K-2026-06-18] [#SEC-8K-2026-06-18]
Prob 35% • Move 45% • Priced-in 25%

Risks

FDA remediation may take longer than expected or fail to support NDA resubmission.
Low coverage and loose peers materially limit valuation confidence.
Manufacturing, leachables, toxicology, and cGMP issues remain execution risks despite no identified clinical deficiencies.
No dated NDA resubmission, approval timeline, verified consensus comparison, or analyst revision data is available.
The August financing increases share count and may create dilution and financing-overhang risk.

Peers

Symbol	Summary
ALGS	Same-sector, similar-market-cap comparator; the packet provides no direct therapeutic overlap, so valuation use is weak.
BYSI	Same-sector, similar-market-cap comparator; useful mainly for small-cap biotech event volatility rather than operating comparability.
LTRN	Same-sector, similar-market-cap comparator with no demonstrated clinical or indication overlap in the packet.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08